Stop guessing.
Start prescribing with confidence.
The first evidence-graded reference library built specifically for peptide therapy. Every compound rated, every claim sourced, every risk documented. The clinical clarity your patients deserve.
From $12.42/mo (billed annually). Cancel anytime. Full access to every monograph.
Peptide therapy is exploding. The evidence base hasn't kept up.
Your patients are already using these compounds. The question is whether they're getting guidance from you or from Reddit.
28
grey-market compounds
Widely used with no FDA oversight, variable purity, and limited human data
8
investigational compounds
In clinical trials with promising data but no approved labeling yet
10
FDA-approved peptides
Full prescribing information, post-marketing safety data, and label summaries
Every compound. One structured reference.
No marketing spin. No vendor links. Just the evidence, graded and cited.
Clinical Monographs
Dual-summary format: one written for clinicians, one for patients. Toggle between clinical depth and plain language.
Evidence Grading
Every compound rated A through D based on the quality and quantity of human clinical data. No inflated claims.
Safety Profiles
Contraindications, adverse events, interactions, and active safety signals. All sourced, never speculative.
Head-to-Head Compare
Put up to 3 compounds side by side. Compare mechanisms, evidence grades, safety signals, and regulatory status.
Cited References
Every claim links to RCTs, FDA labels, meta-analyses, or preclinical studies. With key findings and limitations.
No Conflicts of Interest
No vendor partnerships. No affiliate links. No sponsored content. We sell access to the reference, period.
Six categories. 48 compounds. One source of truth.
Built for clinicians who refuse to wing it
Functional and Integrative MDs
Your patients ask about peptides at every visit. Now you have a reference that matches the rigor you bring to everything else.
Sports Medicine and Longevity Clinics
BPC-157, TB-500, GH secretagogues. Your patients are already using them. Know the evidence grade before you advise.
NPs, PAs, and Clinical Pharmacists
Expanding your scope into peptide therapy? Start with the evidence base, not the marketing materials.
Medical Directors at Med Spas
Offering peptide protocols? The PDR gives you the clinical backbone to stand behind every compound you carry.
See what a monograph looks like
Every compound gets this level of depth. Browse a sample below.
Retatrutide
LY3437943 · Reta
Retatrutide is an investigational weight loss medication that works on three different hormone pathways at once. In clinical trials, people lost an average of about 24% of their body weight over 48 weeks, which is more than currently available medications achieve. It is still being studied and has not yet been approved by the FDA.
Cagrilintide
NN9838 · AM833
Cagrilintide is an investigational medication that mimics a natural hormone called amylin, which helps you feel full after eating. It is being developed as a once-weekly injection for weight management. It is also being studied in combination with semaglutide (a GLP-1 medication) under the name CagriSema, which may produce greater weight loss than either drug alone.
CagriSema
Cagrilintide + Semaglutide · NNC9204-1706 + NNC9204-0530
CagriSema combines two medications in a single weekly injection: semaglutide (which works on the GLP-1 pathway) and cagrilintide (which works on the amylin pathway). By targeting two different hunger-related hormone systems at once, it may produce greater weight loss than either medication alone. It is currently in late-stage clinical trials.
Full access. One flat rate. No surprises.
Every monograph. Every reference. Every safety signal. Updated continuously as new evidence emerges.
- Full clinical monographs for all compounds
- Evidence grading with cited references
- Complete safety profiles and signals
- Side-by-side comparison tool
- Monitoring considerations
- New compounds added regularly
$12.42/mo billed annually. Or $19/mo billed monthly. Cancel anytime.
What we will never do
The PDR exists to inform, not to sell. These guardrails are non-negotiable.
We will never list vendors, sources, or pricing
We will never provide compounding or reconstitution instructions
We will never offer personalized dosing recommendations
We will never accept sponsored content or vendor partnerships
We will never inflate evidence grades to drive interest
We will never omit safety signals to make a compound look favorable
Your patients are asking about peptides today.
Be ready.
Join the clinicians who are done Googling and ready to reference.